Article

Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice

Department Neuroscience, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA.
Neuron (Impact Factor: 15.98). 08/2005; 47(2):191-9. DOI: 10.1016/j.neuron.2005.06.030
Source: PubMed

ABSTRACT Considerable circumstantial evidence suggests that Abeta42 is the initiating molecule in Alzheimer's disease (AD) pathogenesis. However, the absolute requirement for Abeta42 for amyloid deposition has never been demonstrated in vivo. We have addressed this by developing transgenic models that express Abeta1-40 or Abeta1-42 in the absence of human amyloid beta protein precursor (APP) overexpression. Mice expressing high levels of Abeta1-40 do not develop overt amyloid pathology. In contrast, mice expressing lower levels of Abeta1-42 accumulate insoluble Abeta1-42 and develop compact amyloid plaques, congophilic amyloid angiopathy (CAA), and diffuse Abeta deposits. When mice expressing Abeta1-42 are crossed with mutant APP (Tg2576) mice, there is also a massive increase in amyloid deposition. These data establish that Abeta1-42 is essential for amyloid deposition in the parenchyma and also in vessels.

Download full-text

Full-text

Available from: Jason L Eriksen, Aug 12, 2015
0 Followers
 · 
153 Views
  • Source
    • "Despite Ab 1 - 40 is in the majority in the brain of AD patients , Ab 1 - 42 is demonstrated that a major constituent of amyloid plaques . Moreover , Ab 1 - 42 aggregation plays a critical role in the initiation of plaque formation and AD pathogenesis ( McGowan et al . , 2005 ) . Ab vaccine study has showed that Ab 1 - 42 vaccines were efficient in Ab clearance and cognitive improvement ( Buckwalter et al . , 2006 ; Janus et al . , 2000 ; Morgan et al . , 2000 ) . Because Ab 1 - 42 vaccine could induce the body to produce anti - Ab antibodies , and a major proportion of the antibodies were more specific to A"
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-amyloid-β (Aβ) immunotherapy is a potential therapeutic strategy to reduce amyloid plaques and amyloid-associated pathologies in Alzheimer's disease (AD). Immune senescence with aging has also played a crucial role in AD pathogenesis and influences the effect of anti-Aβ immunotherapy. In this study, a combined treatment of Aβ1-42-bone marrow-derived dendritic cells (BMDCs) with intraperitoneal injection of splenocytes from young mice was designed as a novel immunotherapy for AD in APPswe/PSEN1de9 transgenic mice models. The results showed that the combined treatment not only elevated the level of anti-Aβ antibodies but also reduced amyloid plaques in brain and finally ameliorated deterioration of spatial learning and memory in AD mice. Additionally, the results revealed an increase of CD68 positive microglial cells in the vicinity of amyloid plaques in the mouse brain, which was responsible for the enhanced phagocytosis of Aβ plaques. In conclusion, the Aβ1-42-BMDCs plus splenocytes treatment improved the phagocytosis of microglia and prevented AD pathology more effectively. This combined immunotherapy provided a promising treatment in preventing the progression of AD in clinical studies in the near future.
    Neurobiology of Aging 07/2014; 36(1). DOI:10.1016/j.neurobiolaging.2014.06.029 · 4.85 Impact Factor
  • Source
    • "Both C99 and C83 stubs can be cleaved by g-secretase within the transmembrane domain, resulting in the release of Ab or p3 peptides, respectively, and the intracytoplasmic domain of APP (AICD). Because cleavage by g-secretase is heterogeneous, Ab peptides from various lengths can be generated, with Ab1e40 being the most abundant and soluble and the Ab1e42 the most prone to aggregation (Jarret et al., 1993; McGowan et al., 2006). It is noteworthy that APP represents only 1 of several secretase substrates. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A role of amyloid β (Aβ) peptide aggregation and deposition in Alzheimer's disease (AD) pathogenesis is widely accepted. Significantly, abnormalities induced by aggregated Aβ have been linked to synaptic and neuritic degeneration, consistent with the "dying-back" pattern of degeneration that characterizes neurons affected in AD. However, molecular mechanisms underlying the toxic effect of aggregated Aβ remain elusive. In the last 2 decades, a variety of aggregated Aβ species have been identified and their toxic properties demonstrated in diverse experimental systems. Concurrently, specific Aβ assemblies have been shown to interact and misregulate a growing number of molecular effectors with diverse physiological functions. Such pleiotropic effects of aggregated Aβ posit a mayor challenge for the identification of the most cardinal Aβ effectors relevant to AD pathology. In this review, we discuss recent experimental evidence implicating amyloid β precursor protein (APP) as a molecular target for toxic Aβ assemblies. Based on a significant body of pathologic observations and experimental evidence, we propose a novel pathologic feed-forward mechanism linking Aβ aggregation to abnormalities in APP processing and function, which in turn would trigger the progressive loss of neuronal connectivity observed early in AD.
    Neurobiology of aging 05/2013; 34(11). DOI:10.1016/j.neurobiolaging.2013.04.021 · 4.85 Impact Factor
  • Source
    • "Depending on the site of APP cleavage by γ-secre- tase [18] , " chain-length variants " of Aβ peptides are generated in cells. A major constituent of amyloid plaques is Aβ42, aggregation of which has been suggested to play a critical role in the initiation of plaque formation and AD pathogenesis [19] . Purified Aβ42 which exhibits lower solubility is converted into oligomers, protofibrils and fibrils at lower concentrations and higher rates than "
    [Show abstract] [Hide abstract]
    ABSTRACT: Formation of amyloid- () aggregates is a core process in the pathogenesis of Alzheimer's disease. Importance of interaction of the length variants, and in the process and consequent cytotoxicity has been pointed out for wild-type previously. In addition to confirming the findings, the current study demonstrates that the potential interaction is also important for cytotoxicity of the Flemish and Dutch sequence variants. The interaction could strengthen or inhibit cytotoxicity of mixture, depending on interaction time of the length variants as well as the ratio and amyloidogenic property. The inhibitory effect was prominent at the early stage of aggregate formation in less amyloidogenic Flemish mixture, while strengthened cytotoxicity was exhibited at the stage in potently amyloidogenic Dutch variant and at the later stage in wild-type and the Flemish variant. The samples showing relatively robust cytotoxicity were those enriched in protofibril-like structures, implying strong correlation of the structure with cytotoxicity. The different consequence of the interaction on sequence variants is likely due to differential amyloidogenic property of each variant, rather than that of , because aggregation rates and levels of variants are greatly variable depending on the sequence, compared to variants. These studies may highlight a potential role of in the cytotoxicity, providing a novel mechanistic insight into the pathogenesis of each FAD-associated variant.
    03/2013; 6(1). DOI:10.13160/ricns.2013.6.1.021
Show more